Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies

Antiviral Res. 2016 Sep;133:218-222. doi: 10.1016/j.antiviral.2016.08.012. Epub 2016 Aug 13.

Abstract

Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / immunology
  • Antibodies, Viral / pharmacology*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Guinea Pigs
  • Humans
  • Inhibitory Concentration 50
  • Lassa Fever / drug therapy
  • Lassa Fever / immunology
  • Lassa Fever / virology*
  • Lassa virus / drug effects*
  • Lassa virus / immunology
  • Neutralization Tests

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral